FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4231010457> ?p ?o ?g. }

• W4231010457 endingPage "2275" @default.
• W4231010457 startingPage "2275" @default.
• W4231010457 abstract "Abstract Background Gaucher disease type 1 is one of the most common lysosomal storage disorders. Deficiency of the lysosomal enzyme acid-β-glucosidase leads to accumulation of glucosylceramide (GL-1) in the spleen, liver, and bone marrow. Enzyme replacement therapy has been the mainstay of therapy for the last 20 years. Substrate reduction therapy is another treatment approach that inhibits GL-1 synthase and ultimately restores the balance between synthesis and degradation of the substrate. Eliglustat is a novel oral substrate reduction therapy that is currently in development for the treatment of Gaucher disease type 1. ENGAGE (NCT00891202) is a randomized, double-blind, placebo-controlled, Phase 3 trial sponsored by Genzyme, a Sanofi company investigating the efficacy and safety of eliglustat in untreated adults with Gaucher disease type 1. Method Forty patients (mean age: 31.8 years; 20 males) with splenomegaly and thrombocytopenia and/or anemia were stratified by spleen volume and randomized 1:1 to receive eliglustat (50 or 100 mg BID depending on plasma levels) or placebo for 9 months. The primary efficacy endpoint was percent change in spleen volume (multiples of normal). Other efficacy measures included hemoglobin, liver volume, and platelets. Bone endpoints included bone marrow burden (BMB) scores and bone mineral density changes (DXA). Quality of life assessments included the Gaucher Disease Severity Scoring System (DS3). Safety monitoring included adverse event reporting, and lab and electrocardiogram evaluations. Results In patients receiving eliglustat vs. placebo, mean spleen volume decreased (-28% vs. +2%, P<0.0001), mean hemoglobin increased (0.69 vs. -0.54 g/dL, P<0.0006), liver volume decreased (-5.20% vs. +1.44%, P<0.0072), and platelets increased (+32% vs. -9.06%, P<0.0001). Significant improvements (eliglustat vs. placebo) were observed for total (-1.1 vs. 0.0, p=0.002), spine (-0.6 vs. 0.1, p=0.002), and femur (-0.5 vs. 0.0, p=0.026) BMB scores. Although patients with symptomatic bone disease were excluded, absolute change in total spine DXA Z-scores approached significance (least square mean treatment difference=0.2, p=0.06). Burden of disease, as measured by the Gaucher DS3, was significantly reduced following treatment with eliglustat vs. placebo (least square mean treatment difference=-0.3, p=0.0452). No patients discontinued due to an adverse event, all of which were classified as mild to moderate, and 39/40 patients transitioned into the ongoing open-label trial. Arthralgia and nasopharyngitis occurred in >10% of eliglustat vs. placebo patients. Conclusion ENGAGE met its primary and secondary efficacy endpoints. Significant effects on bone marrow and a trend toward BMD improvement in spine were observed. Eliglustat treatment was effective and well-tolerated in untreated adults with Gaucher disease type 1. Disclosures: Shankar: Genzyme, a Sanofi company: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding. Lukina:Genzyme, a Sanofi company: Consultancy, Honoraria, Speakers Bureau. Amato:Genzyme, a Sanofi company: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. Packman:Genzyme, a Sanofi company: Consultancy, Research Funding. Pastores:Genzyme, a Sanofi company: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. Balwani:Genzyme, a Sanofi company: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. Mistry:Genzyme, a Sanofi company: Consultancy, Honoraria, Research Funding. Ross:Genzyme, a Sanofi company: Employment. Marulkar:Genzyme, a Sanofi company: Employment. Peterschmitt:Genzyme, a Sanofi company: Employment." @default.
• W4231010457 created "2022-05-11" @default.
• W4231010457 creator A5015313244 @default.
• W4231010457 creator A5017093187 @default.
• W4231010457 creator A5022252587 @default.
• W4231010457 creator A5022254784 @default.
• W4231010457 creator A5024492632 @default.
• W4231010457 creator A5025310940 @default.
• W4231010457 creator A5027941722 @default.
• W4231010457 creator A5035175130 @default.
• W4231010457 creator A5045319976 @default.
• W4231010457 creator A5055529584 @default.
• W4231010457 creator A5062886426 @default.
• W4231010457 creator A5074729432 @default.
• W4231010457 date "2013-11-15" @default.
• W4231010457 modified "2023-10-01" @default.
• W4231010457 title "Engage: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Study To Investigate The Efficacy and Safety Of Eliglustat In Adults With Gaucher Disease Type 1: 9 Month Results" @default.
• W4231010457 doi "https://doi.org/10.1182/blood.v122.21.2275.2275" @default.
• W4231010457 hasPublicationYear "2013" @default.
• W4231010457 type Work @default.
• W4231010457 citedByCount "1" @default.
• W4231010457 countsByYear W42310104572017 @default.
• W4231010457 crossrefType "journal-article" @default.
• W4231010457 hasAuthorship W4231010457A5015313244 @default.
• W4231010457 hasAuthorship W4231010457A5017093187 @default.
• W4231010457 hasAuthorship W4231010457A5022252587 @default.
• W4231010457 hasAuthorship W4231010457A5022254784 @default.
• W4231010457 hasAuthorship W4231010457A5024492632 @default.
• W4231010457 hasAuthorship W4231010457A5025310940 @default.
• W4231010457 hasAuthorship W4231010457A5027941722 @default.
• W4231010457 hasAuthorship W4231010457A5035175130 @default.
• W4231010457 hasAuthorship W4231010457A5045319976 @default.
• W4231010457 hasAuthorship W4231010457A5055529584 @default.
• W4231010457 hasAuthorship W4231010457A5062886426 @default.
• W4231010457 hasAuthorship W4231010457A5074729432 @default.
• W4231010457 hasConcept C126322002 @default.
• W4231010457 hasConcept C141071460 @default.
• W4231010457 hasConcept C142724271 @default.
• W4231010457 hasConcept C168563851 @default.
• W4231010457 hasConcept C197934379 @default.
• W4231010457 hasConcept C203092338 @default.
• W4231010457 hasConcept C204787440 @default.
• W4231010457 hasConcept C27081682 @default.
• W4231010457 hasConcept C2778248108 @default.
• W4231010457 hasConcept C2779134260 @default.
• W4231010457 hasConcept C2779969927 @default.
• W4231010457 hasConcept C2780007613 @default.
• W4231010457 hasConcept C71924100 @default.
• W4231010457 hasConcept C90924648 @default.
• W4231010457 hasConceptScore W4231010457C126322002 @default.
• W4231010457 hasConceptScore W4231010457C141071460 @default.
• W4231010457 hasConceptScore W4231010457C142724271 @default.
• W4231010457 hasConceptScore W4231010457C168563851 @default.
• W4231010457 hasConceptScore W4231010457C197934379 @default.
• W4231010457 hasConceptScore W4231010457C203092338 @default.
• W4231010457 hasConceptScore W4231010457C204787440 @default.
• W4231010457 hasConceptScore W4231010457C27081682 @default.
• W4231010457 hasConceptScore W4231010457C2778248108 @default.
• W4231010457 hasConceptScore W4231010457C2779134260 @default.
• W4231010457 hasConceptScore W4231010457C2779969927 @default.
• W4231010457 hasConceptScore W4231010457C2780007613 @default.
• W4231010457 hasConceptScore W4231010457C71924100 @default.
• W4231010457 hasConceptScore W4231010457C90924648 @default.
• W4231010457 hasIssue "21" @default.
• W4231010457 hasLocation W42310104571 @default.
• W4231010457 hasOpenAccess W4231010457 @default.
• W4231010457 hasPrimaryLocation W42310104571 @default.
• W4231010457 hasRelatedWork W11910675 @default.
• W4231010457 hasRelatedWork W22021095 @default.
• W4231010457 hasRelatedWork W3197746 @default.
• W4231010457 hasRelatedWork W4802778 @default.
• W4231010457 hasRelatedWork W4862497 @default.
• W4231010457 hasRelatedWork W5032858 @default.
• W4231010457 hasRelatedWork W521266 @default.
• W4231010457 hasRelatedWork W5425512 @default.
• W4231010457 hasRelatedWork W5667359 @default.
• W4231010457 hasRelatedWork W5795428 @default.
• W4231010457 hasVolume "122" @default.
• W4231010457 isParatext "false" @default.
• W4231010457 isRetracted "false" @default.
• W4231010457 workType "article" @default.